The Hindu·4 min read·medium
Trump’s 200% generic tariff threat would imperil Americans: Indian pharma
N
N. Ravi Kumar
✦AI Summary
U.S. President Donald Trump has announced a phased tariff plan reaching 200% on imported generic drugs by 2031 to encourage domestic manufacturing. Indian pharmaceutical companies warn that these measures will likely lead to higher medicine costs for American consumers.
U.S. President Donald Trump has given generic pharmaceutical companies a two-year window to establish manufacturing facilities in the United States, warning that products imported after August 2028 could face tariffs of up to 200%.
economybusinesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in